NephrologyOnline.net

Nephrology Xagena

Search results for "Hyperparathyroidism"

The FDA ( Food and Drug Administration ) has approved Zemplar ( Paricalcitol ) capsules, an oral, activated vitamin D therapy for prevention and treatment of secondary hyperparathyroidism ( SHPT ). ...


In phase 4 IMPACT-SHPT study, efficacy and safety of Paricalcitol-centred therapy were compared with that of Cinacalcet-centred therapy for the treatment of chronic kidney disease (CKD)-associated sec ...